Quercetin, a well-known naturally occurring polyphenol, has recently been shown by molecular docking, in vitro and in vivo studies to be a possible anti-COVID-19 candidate. Quercetin has strong antioxidant, anti-inflammatory, immunomodulatory, and antiviral properties, and it is characterized by a very high safety profile, exerted in animals and in humans. Like most other polyphenols, quercetin shows a very low rate of oral absorption and its clinical use is considered by most of modest utility. Quercetin in a delivery-food grade system with sunflower phospholipids (Quercetin Phytosome®, QP) increases its oral absorption up to 20-fold.

Authors: Hermine O, Mariette X, Tharaux PL, Resche-Rignon M, Porcher R PMID: 33080017 PMCID: PMC7577198 DOI: 10.1001/jamainternmed.2020.6820 Abstract Importance: Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common presentation of coronavirus disease 2019 (COVID-19). Objective: To determine whether tocilizumab (TCZ) improves outcomes of patients hospitalized with moderate-to-severe COVID-19 pneumonia. Design, setting, and particpants: This [...]

In hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia, progression to acute respiratory failure requiring invasive mechanical ventilation (MV) is associated with significant morbidity and mortality.

Authors: Kory P, Kanne JP PMID: 32963028 PMCID: PMC7509945 DOI: 10.1136/bmjresp-2020-000724 Abstract Reviews of COVID-19 CT imaging along with postmortem lung biopsies and autopsies indicate that the majority of patients with COVID-19 pulmonary involvement have secondary organising pneumonia (OP) or its histological variant, acute fibrinous and organising pneumonia, both well-known complications of viral infections. Further, [...]

Authors: von der Thusen J, van der Eerden M PMID: 32353898 PMCID: PMC7267318 DOI: 10.1111/eci.13259 Abstract Background: The clinical features of COVID-19 pneumonia range from a mild illness to patients with a very severe illness with acute hypoxemic respiratory failure requiring ventilation and Intensive Care Unit admission. Aims: To provide a brief overview of the [...]

Authors: Gattinoni L, Chiumello D, Rossi S PMID: 32299472 PMCID: PMC7160817 DOI: 10.1186/s13054-020-02880-z Abstract Even though it can meet the ARDS Berlin definition, the COVID-19 pneumonia is a specific disease with peculiar phenotypes. Its main characteristic is the dissociation between the severity of the hypoxemia and the maintenance of relatively good respiratory mechanics. Indeed, the [...]

Authors: Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L PMID: 32291463 PMCID: PMC7154064 DOI: 10.1007/s00134-020-06033-2 Abstract The Surviving Sepsis Campaign panel recently recommended that “mechanically ventilated patients with COVID-19 should be managed similarly to other patients with acute respiratory failure in the ICU.” Yet, COVID-19 pneumonia, despite falling in most of [...]

Authors: McGonagle D, Sharif K, O'Regan A, Bridgewood C PMID: 32251717 PMCID: PMC7195002 DOI: 10.1016/j.autrev.2020.102537 Abstract Severe COVID-19 associated pneumonia patients may exhibit features of systemic hyper-inflammation designated under the umbrella term of macrophage activation syndrome (MAS) or cytokine storm, also known as secondary haemophagocytic lymphohistocytosis (sHLH). This is distinct from HLH associated with immunodeficiency [...]

Authors: Torrealba JR, Fisher S, Kanne JP, Butt YM, Glazer C, Kershaw C PMID: 29122655 DOI: 10.1016/j.humpath.2017.10.028 Abstract Organizing pneumonia (OP) is a common pattern of lung injury that can be associated with a wide range of etiologies. Typical and not-so-typical imaging features of OP occur, as both common and rare lung pathologies can mimic [...]